Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,258 | 202 | 1,041 |
| Samples | 333 | 84 | 245 |
| Peptides | 265 | 53 | 212 |
Function
EIF4G2 · Eukaryotic translation initiation factor 4 gamma 2
Translation initiation is mediated by specific recognition of the cap structure by eukaryotic translation initiation factor 4F (eIF4F), which is a cap binding protein complex that consists of three subunits: eIF4A, eIF4E and eIF4G. The protein encoded by this gene shares similarity with the C-terminal region of eIF4G that contains the binding sites for eIF4A and eIF3; eIF4G, in addition, contains a binding site for eIF4E at the N-terminus. Unlike eIF4G, which supports cap-dependent and independent translation, this gene product functions as a general repressor of translation by forming translationally inactive complexes. In vitro and in vivo studies indicate that translation of this mRNA initiates exclusively at a non-AUG (GUG) codon. Alternatively spliced transcript variants encoding different isoforms of this gene have been described. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 261 amino-acid changes on canonical ENST00000339995 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in EIF4G2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in EIF4G2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Glioblastoma | 4/98 4% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 18/612 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Unknown | 0/10 0% | 1/29 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Cervical Carcinoma | 6/35 17% | 5/422 1% |
| Melanoma | 8/210 4% | 33/1899 2% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Colorectal Carcinoma | 9/143 6% | 40/3239 1% |
| Bladder Carcinoma | 1/58 2% | 13/956 1% |
| Non-Small Cell Lung Carcinoma | 13/304 4% | 10/1390 1% |
| Neuroendocrine Tumour | 6/154 4% | 2/577 0% |
| Gastric Carcinoma | 1/74 1% | 17/1809 1% |
| Other Solid Cancers | 2/94 2% | 13/1515 1% |
| Burkitts Lymphoma | 0/32 0% | 2/196 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Ovarian Carcinoma | 3/109 3% | 6/998 1% |
| Hepatocellular Carcinoma | 1/46 2% | 14/2210 1% |
| Ewings Sarcoma | 0/63 0% | 2/262 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 12/2550 0% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Head and Neck Carcinoma | 0/85 0% | 8/1574 1% |
| Kidney Carcinoma | 4/85 5% | 5/1862 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Breast Carcinoma | 2/144 1% | 12/3264 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 4/1592 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| B-Cell Non-Hodgkins Lymphoma | 6/88 7% | 1/2534 0% |
Mutation Distribution
Where EIF4G2 is mutated · all tissues, split by cell line vs tissue
How many mutations in EIF4G2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,258 mutations in EIF4G2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|